UY36197A - BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS - Google Patents

BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS

Info

Publication number
UY36197A
UY36197A UY0001036197A UY36197A UY36197A UY 36197 A UY36197 A UY 36197A UY 0001036197 A UY0001036197 A UY 0001036197A UY 36197 A UY36197 A UY 36197A UY 36197 A UY36197 A UY 36197A
Authority
UY
Uruguay
Prior art keywords
human
glatiramer acetate
product derived
mammal cells
biological characterization
Prior art date
Application number
UY0001036197A
Other languages
Spanish (es)
Inventor
Hayden Michael
Grossman Iris
Hasson Tal
Ladkani David
Fadi George Towfic
Sarah Elisabeth Kolitz
Benjamin James Zeskind
Hayardeny Liat
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY36197A publication Critical patent/UY36197A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee un proceso de caracterización de una sustancia o producto farmacológico relacionado con acetato de glatiramer que comprende los pasos de: a) obtener un lote de la sustancia o producto farmacológico relacionado con acetato de glatiramer; b) poner en contacto células de mamífero con una cantidad de la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a); y c) determinar el nivel de expresión de al menos uno de los genes descritos en este documento, caracterizando así la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a).The present invention provides a process for characterizing a substance or drug product related to glatiramer acetate comprising the steps of: a) obtaining a batch of the drug substance or product related to glatiramer acetate; b) contacting mammalian cells with an amount of the substance or drug product related to glatiramer acetate from step a); and c) determining the level of expression of at least one of the genes described herein, thus characterizing the drug substance or product related to glatiramer acetate from step a).

UY0001036197A 2014-07-01 2015-06-29 BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS UY36197A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019857P 2014-07-01 2014-07-01
US201462020358P 2014-07-02 2014-07-02
US201462025953P 2014-07-17 2014-07-17
US201462047437P 2014-09-08 2014-09-08
US201462078369P 2014-11-11 2014-11-11
US201562134245P 2015-03-17 2015-03-17
US201562162308P 2015-05-15 2015-05-15

Publications (1)

Publication Number Publication Date
UY36197A true UY36197A (en) 2016-01-29

Family

ID=55020098

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036197A UY36197A (en) 2014-07-01 2015-06-29 BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS

Country Status (6)

Country Link
EP (1) EP3164710A4 (en)
CA (1) CA2952849A1 (en)
IL (1) IL249686A0 (en)
TW (1) TW201610169A (en)
UY (1) UY36197A (en)
WO (1) WO2016004250A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053109A1 (en) * 2016-09-14 2018-03-22 Teva Pharmaceutical Industries Ltd. Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells
CN116637123B (en) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） Application of reagent for knocking down or down expression of C15orf39 gene in preparation of medicines for treating gastric cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530975A (en) * 2007-06-21 2010-09-16 モメンタ ファーマシューティカルズ インコーポレイテッド Copolymer assay

Also Published As

Publication number Publication date
WO2016004250A3 (en) 2016-03-17
EP3164710A4 (en) 2018-04-11
TW201610169A (en) 2016-03-16
CA2952849A1 (en) 2016-01-07
EP3164710A2 (en) 2017-05-10
IL249686A0 (en) 2017-02-28
WO2016004250A2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
PE20151980A1 (en) CHARACTERIZATION OF A GLATIRAMER ACETATE RELATED MEDICINAL PRODUCT
EA201890013A1 (en) METHODS FOR OBTAINING TCR GAMMA DELTAT-CELLS
CO2017000507A2 (en) Chimeric bcma antigen receptor
MX2021008142A (en) Methods for harvesting mammalian cell cultures.
WO2016040862A3 (en) Integration of auxiliary sensors with point cloud-based haptic rendering and virtual fixtures
BR112014000965B8 (en) METHOD, APPLIANCE AND NON-TRAINER STORAGE MEDIA
BR112017007965A2 (en) computer-implemented method for inferring the activity of a tgf-b cell signaling pathway in an individual; apparatus for inferring the activity of a tgf-b cellular signaling pathway in an individual; non-transient storage medium; computer program; kits for measuring expression levels of three or more tgf-b cell signaling pathway target genes in a sample from an individual; infer the activity of a tgf-b cell signaling pathway in an individual; infer the activity of a tgf-b cell signaling pathway in an individual; and use of the kit
EA202092987A3 (en) LIPID CONTAINING DOCOSAPENTAENIC ACID
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
CY1122612T1 (en) METHOD
CO2017006156A2 (en) A method to manufacture a protein of interest, where said protein is expressed in a host cell
BR112016024494A2 (en) peptide analogs with branched amino acid probe (s)
UY36870A (en) NEW INSULIN ANALOGS
CO2017005773A2 (en) Compositions, devices, and ibs sensitivity test methods
EA201791275A1 (en) METHODS OF OBTAINING CTP-MODIFIED POLYPEPTIDES OF LONG-TERM
BR112016024895A2 (en) secretory protein factor with high secretory efficacy and an expression vector comprising the same
CL2016002632A1 (en) Arm calibration system
MX2017001979A (en) In vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment.
MX2022003399A (en) Cellular-based method for determining the potency of defibrotide.
MX2017014247A (en) Methods for assesing the purity of a mesenchymal stem cells preparation.
BR112018000168A2 (en) A manufacturing method of a quality iPS cell
UY36197A (en) BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS
WO2015121636A3 (en) Fuel source, fuel cell system and associated method
WO2015068075A3 (en) Detection of tau
AR101088A1 (en) BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220629